Enterprise Therapeutics

Pipeline & Clinical Trials

DMD Voice: Qualitative Interviews With Patients and Caregivers

Duchenne Muscular Dystrophy (DMD)

N/A

Clinical Trials (1)

NCT06925269DMD Voice: Qualitative Interviews With Patients and Caregivers

N/A

Nanoone Woman Underwear

Dysmenorrhea

N/A

Clinical Trials (1)

NCT01449305Effectiveness of Nanoone Woman Underwear Using in the Management of Dysmenorrhea

N/A

Placebo

Prediabetes

N/A

Clinical Trials (1)

NCT02300181Effect of the Extract of the Flour Fermented With Bacillus Subtilis Var Natto DC-15 on Postprandial Glucose

N/A

Sixty device

End Stage Renal Disease

N/A

BOSCOGEN 18% Protein ONS: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g

ESRD (End-Stage Renal Disease)

N/A

Clinical Trials (1)

NCT07060040The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status

N/A

Screening for DM, ASCVD, MetS and OSAS

Diabetes Mellitus

N/A

Clinical Trials (1)

NCT03459638Periodontitis as Signal for an Underlying Disease

N/A

Online disease surveillance data access

Communicable Diseases

N/A

Clinical Trials (1)

NCT01232686Snow Disease Surveillance System Study

N/A

NEAA

Metabolism

N/A

Clinical Trials (1)

NCT05020808The Effect of a Plant Protein Isolate on Muscle Protein Synthesis in Humans at Rest and After Resistance Exercise

N/A

Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule

Acne Vulgaris

N/A

Clinical Trials (1)

NCT05855629"A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients."

N/A

Light Intervention

Myopia

N/A

Clinical Trials (1)

NCT06631339Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN)

N/A

Recombinant Human Papillomavirus Bivalent

Cervical Intraepithelial Neoplasia

N/A

multidisciplinary treatment

Acute Admitted Multimorbid Patients

N/A

Clinical Trials (1)

NCT02336113Oslo Pharmacist Intervention Study - Effect on Readmissions

N/A

Eefooton oral solution

Chronic Kidney Diseases

N/A

Clinical Trials (1)

NCT05227313Double-Blind, Placebo-Controlled Trial of Eefooton in Patients With Chronic Kidney Disease

N/A

Clinical Evaluation

Buccal Mucosa Cancer

N/A

Clinical Trials (1)

NCT03137953Role of Imaging to Predict the Deep Surgical Margin in Gingivobuccal Complex Tumors

N/A

Intervention with Microfinance for AIDS and Gender Equity

HIV Infections

N/A

Clinical Trials (1)

NCT00242957The Intervention With Microfinance for AIDS and Gender Equity (IMAGE) Study

N/A

Modified Trans-Esophageal Prosthesis

Laryngeal Cancer

N/A

Clinical Trials (1)

NCT03039465A Novel Modified Tracheo-Esophageal Voice Prosthesis for Total Laryngectomy Patients

N/A

SynEx Wound Cleanser

Wound Heal

N/A

Clinical Trials (1)

NCT05743283Efficacy of SynEx Wound Rinse in Civilian Surrogates of Combat Injury Wounds

N/A

Recombinant Human Papillomavirus Bivalent

Cervical Intraepithelial Neoplasia

N/A

Commercial Kombucha tea

Schizophrenia

N/A

Clinical Trials (1)

NCT06502509Kombucha Tea for Improving Defecation in Patients With Schizophrenia- a Randomized Controlled Study

N/A

F-Point

Low Fibrinogen

N/A

Clinical Trials (1)

NCT03623061F-Point Validation Study

N/A

Pea-protein concentrate

Bioavailability of Amino Acids Following Oral Ingestion of Plant-Based Proteins in Young, Healthy Men

N/A

Clinical Trials (1)

NCT04872530Bioavailability of Plant Protein Amino Acids

N/A

Patient Pathway Pharmacist intervention

Hip Fractures

N/A

Clinical Trials (1)

NCT03695081Patient Pathway Pharmacist - Optimal Drug-related Care

N/A

SEE Change Business and Personal Agency Training

Well-Being, Psychological

N/A

Clinical Trials (1)

NCT05958225SEE Change Evaluation - Impacts of Personal Agency Training on Ugandan Entrepreneurs

N/A

Compression Therapy System Prototype

Venous Leg Ulcer

N/A

Clinical Trials (1)

NCT05610241Preliminary Investigation of a Smart Compression Therapy Prototype

N/A

19 gauge needle

Sarcoidosis

N/A

nCLE aided RANB biospy

Lung Neoplasms

N/A

Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement

Bone Resorption

N/A

Clinical Trials (1)

NCT05533502Combination Plant-Based Protein and Marine-Based Multi-Mineral Supplement and Bone Remodeling in Young Adults

N/A

Inhalation technique training and discharge service

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT03691324Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study

N/A

3 doses of HPV 16/18 bivalent vaccine

Cervical Intraepithelial Neoplasia

N/A

Remote Administration of NSAA

Duchenne Muscular Dystrophy

N/A

Clinical Trials (1)

NCT06054971NSAA NON-Interventional Study Protocol

N/A

MICS CABG

Coronary Artery Disease

N/A

Clinical Pharmacist Intervention

Severe Mental Illness

N/A

Transcranial Electric Stimulation

Sleep

N/A

Clinical Trials (1)

NCT07608614Sleep and Performance

N/A

In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Aci

Cardiovascular Diseases

N/A

Clinical Trials (1)

NCT01777516In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Acid

N/A

NUIG OAB App

Overactive Bladder

N/A

Clinical Trials (1)

NCT05170100Evaluating a Digital Intervention for Overactive Bladder

N/A

Premium Amino Acids

Colorectal Cancer

N/A

Clinical Trials (1)

NCT04567459The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study

N/A

Water Control

Insulin Resistance

N/A

Clinical Trials (1)

NCT03102463The Role of Milk Derived Peptides on Glycaemic Control

N/A

Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers

COPD

N/A

Clinical Trials (1)

NCT02490358Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers

N/A

Scales

Stroke

N/A

Clinical Trials (1)

NCT02793934The Pilot Project Development Of MEdical Rehabilitation System in Russian Federation

N/A

Active breaks

Physical Activity

N/A

KneeStim

Anterior Cruciate Ligament Injuries

N/A

Clinical Trials (1)

NCT06341868Dynamic Muscular Electrical Stimulation Following Anterior Cruciate Ligament Reconstruction in Military Academy Cadets

N/A

Pharmacogenetic test

Admitted Multimorbid Patients

N/A

Clinical Trials (1)

NCT04573491Implementation of Pharmacogenetic Testing in Hospital Wards

N/A

rice protein RP-80N

Healthy

N/A

Clinical Trials (1)

NCT05560048Anti-exercise-fatigue Effects of Rice Protein RP-80NY in Men

N/A

Recombinant Human Papillomavirus Bivalent

Cervical Intraepithelial Neoplasia

N/A

Transforming Powder Dressing

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT05046158Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care

N/A

Dynamic Lighting

Sleep

N/A

Clinical Trials (1)

NCT05697757Lighting for Older Adults With Dementia

N/A

Medication reconciliation at the ICU

Medicines Reconciliation

N/A

Clinical Trials (1)

NCT03173690Medicines Reconciliation at an Intensive Care Unit

N/A

RiSolve

Overactive Bladder (OAB)

N/A

Clinical Trials (1)

NCT07206446A Prospective Evaluation of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women: The RiSolve Trial

N/A

A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Prev

Cardiovascular Diseases

N/A

Recombinant Human Papillomavirus Nonavalent

Cervical Cancer

N/A

NAFTIFINE HYDROCHLORIDE

naftifine hydrochloride

Post-LOE

TOPICAL · CREAM

12.1 Mechanism of Action Naftifine hydrochloride gel is a topical antifungal drug [see ] . 12.2 Pharmacodynamics The pharmacodynamics of naftifine hydrochloride gel have not been established. 12.3 Pharmacokinetics In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes. Pharmacokinetic analysis of plasma samples from 32 subjects with tinea pedis treated with a mean dose of 3.9 grams naftifine hydrochloride gel applied once daily to both feet for 14 days showed increased exposure over the treatment period, with a geometric mean (CV%) AUC 0-24 (area under plasma concentration-versus-time curve from time 0 to 24 hours) of 10.5 (118) ng∙hr/mL on Day 1 and an AUC 0-24 of 70 (59) ng∙hr/mL on Day 14. The accumulation ratio based on AUC was approximately 6. Maximum concentration (C max ) also increased over the treatment period; geometric mean (CV%) C max after a single dose was 0.9 (92) ng/mL on Day 1; C max on Day 14 was 3.7 (64) ng/mL. Median T max was 20 hours (range: 8, 20 hours) after a single application on Day 1 and 8 hours (range: 0, 24 hours) on Day 14. Trough plasma concentrations increased during the trial period and reached steady state after 11 days. In the same pharmacokinetic trial, the fraction of dose excreted in urine during the treatment period was less than or equal to 0.01% of the applied dose. In a second trial, the pharmacokinetics of naftifine hydrochloride gel was evaluated in 22 pediatric subjects 12 to 17 years of age with tinea pedis. Subjects were treated with a mean dose of 4.1 grams naftifine hydrochloride gel applied to the affected area once daily for 14 days. The results showed that the systemic exposure increased over the treatment period. Geometric mean (CV%) AUC 0-24 was 15.9 (212) ng∙hr/mL on Day 1 and 60 (131) ng∙hr/mL on Day 14. Geometric mean (CV%) C max after a single dose was 1.40 (154) ng/mL on Day 1 and 3.81 (154) ng/mL on Day 14. The fraction of dose excreted in urine during the treatment period was less than or equal to 0.003% of the applied dose. 12.4 Microbiology Mechanism of Action Naftifine is an antifungal that belongs to the allylamine class. Although the exact mechanism of action against fungi is not known, naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. The inhibition of enzyme activity by this allylamine results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells. Mechanism of Resistance To date, a mechanism of resistance to naftifine has not been identified. Naftifine has been shown to be active against most isolates of the following fungi, both in vitro and in clinical infections, as described in the INDICATIONS AND USAGE section: Trichophyton rubrum Trichophyton mentagrophytes Epidermophyton floccosum

2020

About Enterprise Therapeutics

Key Products

Products & Portfolio (15)

Key Products by Revenue

Other Products (7)

Pipeline & Clinical Trials

Open Jobs (0)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)